FY2024 EPS Estimates for Co-Diagnostics Lifted by Analyst

Co-Diagnostics, Inc. (NASDAQ:CODX) – Analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Co-Diagnostics in a research note issued to investors on Monday, November 11th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($1.22) for the year, up from their prior estimate of ($1.23). HC Wainwright currently has a “Neutral” rating and a $1.50 target price on the stock. The consensus estimate for Co-Diagnostics’ current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Co-Diagnostics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.17) EPS.

Co-Diagnostics Stock Performance

NASDAQ:CODX opened at $1.11 on Thursday. The company has a market cap of $35.44 million, a price-to-earnings ratio of -0.80 and a beta of -0.84. Co-Diagnostics has a 52-week low of $1.00 and a 52-week high of $2.23. The stock’s fifty day moving average price is $1.24 and its two-hundred day moving average price is $1.26.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Co-Diagnostics stock. Koss Olinger Consulting LLC purchased a new stake in Co-Diagnostics, Inc. (NASDAQ:CODX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 58,887 shares of the company’s stock, valued at approximately $74,000. Koss Olinger Consulting LLC owned about 0.19% of Co-Diagnostics at the end of the most recent reporting period. 14.99% of the stock is owned by hedge funds and other institutional investors.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.